More recently, ADAR1 has been identified as a potential determinant of resistance to ICB due to the repression of MDA5- and PKR-mediated dsRNA sensing [235] or ZBP1-mediated Z-RNA sensing [236], which resulted in impairment of tumour inflammation, immune infiltration, and interferon-mediated tumour growth arrest, or RIPK3-mediated necroptosis of tumour cells, respectively. The gene discussed is RIPK3; the disease is neoplasm.